<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753519</url>
  </required_header>
  <id_info>
    <org_study_id>080212</org_study_id>
    <secondary_id>08-N-0212</secondary_id>
    <nct_id>NCT00753519</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation to Treat Parkinson's Disease</brief_title>
  <official_title>Intermittent Theta-Burst Transcranial Magnetic Stimulation (TBS) for the Treatment of Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Hallett</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the effects of transcranial magnetic stimulation (TMS) on symptoms of
      Parkinson's disease. TMS is a method of brain stimulation that may be able to change the
      activity of the nerve cells of the brain. This study will examine the effects of a specific
      pattern of stimulation called intermittent theta-burst TMS (iTBS), which uses repeated
      magnetic pulses delivered in short bursts.

      People with mild to moderately severe Parkinson's disease who are between 40 and 80 years of
      age and whose main problems are slow movement and stiffness may be eligible for this study.

      Participants undergo the following tests and procedures:

        -  Random assignment to real or placebo (sham) iTBS treatment.

        -  iTBS sessions (real or sham) 4 times a week for 2 consecutive weeks. For this test, the
           subject sits in a comfortable chair. A wire coil is held on the subject's scalp, and a
           brief electrical current is passed through the coil, creating a magnetic pulse that
           stimulates the brain. The subject hears a click and may feel a pulling sensation on the
           skin under the coil. There may be a twitch in the muscles of the face, arm or leg.

        -  Test of gait (walk), hand and arm movements before and after each session. The gait test
           requires walking 10 meters (about 30 yards) in the same corridor with the same shoes.

        -  Extended testing. The first and last gait tests (done before starting iTBS and after the
           eighth session) require coming off any Parkinson's medication for at least 12 hours
           before the test. On these test days, subjects also undergo a clinical examination, short
           neuropsychological test battery, a computer-based reaction time test and depression and
           quality-of-life rating scales. These procedures are repeated in a follow-up visit 1
           month after the last session.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective

      To demonstrate cumulative and long-lasting improvement of parkinsonian symptoms by iTBS and
      its safety in PD patients.

      Study population

      Patients (40-80 years of age) with PD, Hoehn and Yahr disease stage of 2 to 4 while off,
      being on a regimen including levodopa with a total dose of medication equal to more than 300
      mg of levodopa, including their dopamine agonist agents, and having problems with walking and
      needing 6 seconds or more to walk a 10-meter distance.

      Design

      Randomized, double-blind, placebo (sham)-controlled study. Enrollment of 30 patients with PD
      in 2 groups (real versus sham stimulation). Performance (8 interventions) of iTBS with large
      circular coil over motor and prefrontal cortex on both sides. Assessment with standard tests
      of motor function over a one-month period.

      Outcome measure

      The primary endpoint is change in gait speed as assessed by the time it takes to walk 10 m.

      Secondary endpoints include changes in bradykinesia as assessed by measuring the time it
      takes to do ten combined hand and arm movements, and in total and motor UPDRS score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gait Speed</measure>
    <time_frame>baseline, 1 day post iTBS</time_frame>
    <description>Gait speed was assessed by measuring the time it takes to walk 10 meters. Subject's gait speed was measured while on medication and off medication for each group, i.e., real iTBS and sham iTBS. Two trials were averaged for each condition. Patients were instructed to walk fast without taking the risk of falling, wearing the same shoes and consistently using assistive devices if needed. Gait speed was measured at baseline, 1 day post intervention, and 1 month post intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bradykinesia</measure>
    <time_frame>baseline, 1 day post iTBS</time_frame>
    <description>Bradykinesia refers to the slowness in executing a movement. Bradykinesia was assessed by measuring the time in seconds it takes to do the following sequence, 10 times: 1) hand closing and opening while squeezing a ball 2) elbow flexion 3) hand closing and opening, and 4) elbow extension. Subjects were allowed to practice these hand and arm movements until performance appeared not to get faster, and then were abstained from further practice to minimize learning effects. The time it takes subjects to execute the entire sequence 10 times with either the left or right arm/hand was measured. Means are reported for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total UPDRS Score</measure>
    <time_frame>baseline, 1 day post iTBS</time_frame>
    <description>The Total Unified Parkinson's Disease Rating Scale (UPDRS) is an overall assessment scale that quantifies the signs and symptoms of Parkinson's disease. The total UPDRS score consists of mentation, behavior, mood, activities of daily living and motor components, and ranges from 0 (not affected) to 176 (most severely affected). The total UPDRS score is obtained from patient examination, interview and patient questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor UPDRS</measure>
    <time_frame>baseline, 1 day post iTBS</time_frame>
    <description>The Motor Unified Parkinson's Disease Rating Scale (UPDRS) includes only the motor assessment of the UPDRS (Part III) and examines speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability and body bradykinesia. The scores range from 0 (no motor impairment) to 108 (severe motor impairment).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Real iTBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes that standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals. The 2 sec trains were repeated 20 times every 10 sec. iTBS was applied to the primary motor and the dorsolateral prefrontal cortex bilaterally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham iTBS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The sham coil was placed in the same areas, and made a similar sound as the rTMS but was without a magnetic pulse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Real iTBS</intervention_name>
    <description>Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.</description>
    <arm_group_label>Real iTBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham iTBS</intervention_name>
    <description>Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.</description>
    <arm_group_label>Sham iTBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Men and women aged 40 to 80 years with DOPA-responsive PD

          -  Hoehn and Yahr grade of 2 to 4 while off

          -  Must be on a regimen including levodopa.

          -  Total dose of levodopa and dopamine agonists (using dopamine equivalents) has to be
             equal to or more than 300 milligrams per day

          -  Problems with walking, including freezing gait time for a 10-meter distance greater
             than six seconds or more

        EXCLUSION CRITERIA:

          -  Any active psychiatric disease or evidence of dementia

          -  History of seizures and epilepsy

          -  Concurrent use of tricyclic antidepressants, neuroleptic agents, or any other licit or
             illicit drugs other than anti-parkinsonian agents that could lower the seizure
             threshold except for SSRI

          -  Pallidotomy, implanted electrodes and generator for deep brain stimulation

          -  Pregnancy

          -  Surgically or traumatically implanted foreign bodies such as a pacemaker, implanted
             medical pump, implanted hearing aids, metal plate in the skull, or metal implant in
             the skull or eyes (other than dental appliances or fillings) that may pose a physical
             hazard during TEP.

          -  Study would cause undue risk or stress for reasons such as tendency to fall, excessive
             fatigue, general frailty, or excessive apprehensiveness.

          -  Dementia as assessed by the Folstein's Mini-Mental Test Examination (MMSE less than or
             equal to 24/30) or mentally impaired patients having no capacity to provide their own
             consent (the physician establishing the diagnosis and applying UPDRS will evaluate
             patient's mental capacity using conventional clinical interview)

          -  Unable to walk a 10-meter distance.

          -  More than occasional falls, i.e. daily falls (corresponding to a score greater than or
             equal to 3 and more in UPDRS item 13), history of fall(s) with significant injuries,
             absence of postural response in the on condition and/or spontaneous loss of balance in
             the off condition (corresponding to a score of greater than or equal to 2 and greater
             than or equal to 3 in on/off condition, respectively, in UPDRS item 30)

        Pregnancy is unusual in patients with PD, grade 2-4. Urine sample for the pregnancy test
        will be obtained in patients of childbearing potential prior to the iTBS start, at the day
        of the initial interview and signing the consent form. Women of childbearing potential will
        be asked to take appropriate measures to prevent a pregnancy during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aarsland D, Larsen JP, Waage O, Langeveld JH. Maintenance electroconvulsive therapy for Parkinson's disease. Convuls Ther. 1997 Dec;13(4):274-7.</citation>
    <PMID>9437571</PMID>
  </reference>
  <reference>
    <citation>Baudewig J, Siebner HR, Bestmann S, Tergau F, Tings T, Paulus W, Frahm J. Functional MRI of cortical activations induced by transcranial magnetic stimulation (TMS). Neuroreport. 2001 Nov 16;12(16):3543-8.</citation>
    <PMID>11733708</PMID>
  </reference>
  <reference>
    <citation>Belmaker RH, Grisaru N. Magnetic stimulation of the brain in animal depression models responsive to ECS. J ECT. 1998 Sep;14(3):194-205. Review.</citation>
    <PMID>9773358</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2008</study_first_submitted>
  <study_first_submitted_qc>September 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <results_first_submitted>August 31, 2012</results_first_submitted>
  <results_first_submitted_qc>October 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2012</results_first_posted>
  <last_update_submitted>October 14, 2012</last_update_submitted>
  <last_update_submitted_qc>October 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Mark Hallett</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Brain Stimulation</keyword>
  <keyword>Motor Cortex</keyword>
  <keyword>Bradykinesia</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Real iTBS</title>
          <description>iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes than standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals.</description>
        </group>
        <group group_id="P2">
          <title>Sham iTBS</title>
          <description>Sham iTBS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Real iTBS</title>
          <description>iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes than standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals.</description>
        </group>
        <group group_id="B2">
          <title>Sham iTBS</title>
          <description>Sham iTBS</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="6.9"/>
                    <measurement group_id="B2" value="65.6" spread="9.0"/>
                    <measurement group_id="B3" value="63.85" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of disease</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="7.1"/>
                    <measurement group_id="B2" value="6.5" spread="3.4"/>
                    <measurement group_id="B3" value="8.62" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hoehn-Yahr &quot;on&quot;</title>
          <description>The Hoehn and Yahr scale is a system used to describe how the symptoms of Parkinson's disease progress. The scale ranges from 1-5 with 1 representing unilateral involvement with minimal or no functional disability and 5 representing confinement to bed or wheelchair unless aided. The Hoehn and Yahr measurement was taken while the subject was on dopaminergic medication.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="0.2"/>
                    <measurement group_id="B2" value="2.5" spread="0.1"/>
                    <measurement group_id="B3" value="2.52" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hoehn-Yahr &quot;off&quot;</title>
          <description>The Hoehn and Yahr scale is a system used to describe how the symptoms of Parkinson's disease progress. The scale ranges from 1-5 with 1 representing unilateral involvement with minimal or no functional disability and 5 representing confinement to bed or wheelchair unless aided. The Hoehn and Yahr measurement was taken while the subject was off dopaminergic medication for 12 hours or more (overnight).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" spread="0.4"/>
                    <measurement group_id="B2" value="2.9" spread="0.2"/>
                    <measurement group_id="B3" value="2.90" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total LED</title>
          <description>Total levodopa equivalent dose</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1180.9" spread="662.4"/>
                    <measurement group_id="B2" value="732.3" spread="344.8"/>
                    <measurement group_id="B3" value="956.6" spread="565.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tremor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Presence of tremor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of tremor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gait freezing</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Presence of gait freezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of gait freezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fluctuations</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Presence of fluctuations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of flucuations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyskinesias</title>
          <description>Presence or absence of dyskinesias (diminished voluntary movements and the presence of involuntary movements).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Presence of dyskinesias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of dyskinesias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Falls</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Presence of falls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of falls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gait Speed</title>
        <description>Gait speed was assessed by measuring the time it takes to walk 10 meters. Subject's gait speed was measured while on medication and off medication for each group, i.e., real iTBS and sham iTBS. Two trials were averaged for each condition. Patients were instructed to walk fast without taking the risk of falling, wearing the same shoes and consistently using assistive devices if needed. Gait speed was measured at baseline, 1 day post intervention, and 1 month post intervention.</description>
        <time_frame>baseline, 1 day post iTBS</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Medication Real iTBS</title>
            <description>Subjects ON medication while receiving REAL iTBS</description>
          </group>
          <group group_id="O2">
            <title>On Medication Sham iTBS</title>
            <description>Subjects ON medication while receiving SHAM iTBS</description>
          </group>
          <group group_id="O3">
            <title>Off Medication Real iTBS</title>
            <description>Subjects OFF medication while receiving REAL iTBS</description>
          </group>
          <group group_id="O4">
            <title>Off Medication Sham iTBS</title>
            <description>Subjects OFF medication while receiving SHAM iTBS</description>
          </group>
        </group_list>
        <measure>
          <title>Gait Speed</title>
          <description>Gait speed was assessed by measuring the time it takes to walk 10 meters. Subject's gait speed was measured while on medication and off medication for each group, i.e., real iTBS and sham iTBS. Two trials were averaged for each condition. Patients were instructed to walk fast without taking the risk of falling, wearing the same shoes and consistently using assistive devices if needed. Gait speed was measured at baseline, 1 day post intervention, and 1 month post intervention.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" spread="1.98"/>
                    <measurement group_id="O2" value="8.41" spread="1.98"/>
                    <measurement group_id="O3" value="25.84" spread="26.1"/>
                    <measurement group_id="O4" value="8.80" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 day post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68" spread="2.02"/>
                    <measurement group_id="O2" value="7.96" spread="2.02"/>
                    <measurement group_id="O3" value="10.88" spread="3.81"/>
                    <measurement group_id="O4" value="8.20" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bradykinesia</title>
        <description>Bradykinesia refers to the slowness in executing a movement. Bradykinesia was assessed by measuring the time in seconds it takes to do the following sequence, 10 times: 1) hand closing and opening while squeezing a ball 2) elbow flexion 3) hand closing and opening, and 4) elbow extension. Subjects were allowed to practice these hand and arm movements until performance appeared not to get faster, and then were abstained from further practice to minimize learning effects. The time it takes subjects to execute the entire sequence 10 times with either the left or right arm/hand was measured. Means are reported for each group.</description>
        <time_frame>baseline, 1 day post iTBS</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Medication Real iTBS</title>
            <description>Subjects ON medication while receiving REAL iTBS</description>
          </group>
          <group group_id="O2">
            <title>On Medication Sham iTBS</title>
            <description>Subjects ON medication while receiving SHAM iTBS</description>
          </group>
          <group group_id="O3">
            <title>Off Medication Real iTBS</title>
            <description>Subjects OFF medication while receiving REAL iTBS</description>
          </group>
          <group group_id="O4">
            <title>Off Medication Sham iTBS</title>
            <description>Subjects OFF medication while receiving SHAM iTBS</description>
          </group>
        </group_list>
        <measure>
          <title>Bradykinesia</title>
          <description>Bradykinesia refers to the slowness in executing a movement. Bradykinesia was assessed by measuring the time in seconds it takes to do the following sequence, 10 times: 1) hand closing and opening while squeezing a ball 2) elbow flexion 3) hand closing and opening, and 4) elbow extension. Subjects were allowed to practice these hand and arm movements until performance appeared not to get faster, and then were abstained from further practice to minimize learning effects. The time it takes subjects to execute the entire sequence 10 times with either the left or right arm/hand was measured. Means are reported for each group.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.69" spread="5.33"/>
                    <measurement group_id="O2" value="13.25" spread="5.33"/>
                    <measurement group_id="O3" value="17.23" spread="8.10"/>
                    <measurement group_id="O4" value="14.20" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 day post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.32" spread="3.48"/>
                    <measurement group_id="O2" value="10.88" spread="3.48"/>
                    <measurement group_id="O3" value="14.20" spread="7.78"/>
                    <measurement group_id="O4" value="10.80" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total UPDRS Score</title>
        <description>The Total Unified Parkinson's Disease Rating Scale (UPDRS) is an overall assessment scale that quantifies the signs and symptoms of Parkinson's disease. The total UPDRS score consists of mentation, behavior, mood, activities of daily living and motor components, and ranges from 0 (not affected) to 176 (most severely affected). The total UPDRS score is obtained from patient examination, interview and patient questionnaires.</description>
        <time_frame>baseline, 1 day post iTBS</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Medication Real iTBS</title>
            <description>Subjects ON medication while receiving REAL iTBS</description>
          </group>
          <group group_id="O2">
            <title>On Medication Sham iTBS</title>
            <description>Subjects ON medication while receiving SHAM iTBS</description>
          </group>
          <group group_id="O3">
            <title>Off Medication Real iTBS</title>
            <description>Subjects OFF medication while receiving REAL iTBS</description>
          </group>
          <group group_id="O4">
            <title>Off Medication Sham iTBS</title>
            <description>Subjects OFF medication while receiving SHAM iTBS</description>
          </group>
        </group_list>
        <measure>
          <title>Total UPDRS Score</title>
          <description>The Total Unified Parkinson's Disease Rating Scale (UPDRS) is an overall assessment scale that quantifies the signs and symptoms of Parkinson's disease. The total UPDRS score consists of mentation, behavior, mood, activities of daily living and motor components, and ranges from 0 (not affected) to 176 (most severely affected). The total UPDRS score is obtained from patient examination, interview and patient questionnaires.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.54" spread="15.81"/>
                    <measurement group_id="O2" value="57.15" spread="15.81"/>
                    <measurement group_id="O3" value="77.85" spread="17.05"/>
                    <measurement group_id="O4" value="65.92" spread="17.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 day post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.08" spread="16.37"/>
                    <measurement group_id="O2" value="47.62" spread="16.37"/>
                    <measurement group_id="O3" value="70.85" spread="16.26"/>
                    <measurement group_id="O4" value="70.85" spread="16.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Motor UPDRS</title>
        <description>The Motor Unified Parkinson's Disease Rating Scale (UPDRS) includes only the motor assessment of the UPDRS (Part III) and examines speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability and body bradykinesia. The scores range from 0 (no motor impairment) to 108 (severe motor impairment).</description>
        <time_frame>baseline, 1 day post iTBS</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Medication Real iTBS</title>
            <description>Subjects ON medication while receiving REAL iTBS</description>
          </group>
          <group group_id="O2">
            <title>On Medication Sham iTBS</title>
            <description>Subjects ON medication while receiving SHAM iTBS</description>
          </group>
          <group group_id="O3">
            <title>Off Medication Real iTBS</title>
            <description>Subjects OFF medication while receiving REAL iTBS</description>
          </group>
          <group group_id="O4">
            <title>Off Medication Sham iTBS</title>
            <description>Subjects OFF medication while receiving SHAM iTBS</description>
          </group>
        </group_list>
        <measure>
          <title>Motor UPDRS</title>
          <description>The Motor Unified Parkinson's Disease Rating Scale (UPDRS) includes only the motor assessment of the UPDRS (Part III) and examines speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability and body bradykinesia. The scores range from 0 (no motor impairment) to 108 (severe motor impairment).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.00" spread="12.86"/>
                    <measurement group_id="O2" value="37.54" spread="12.86"/>
                    <measurement group_id="O3" value="49.00" spread="12.88"/>
                    <measurement group_id="O4" value="45.69" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 day post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.08" spread="12.13"/>
                    <measurement group_id="O2" value="32.31" spread="12.13"/>
                    <measurement group_id="O3" value="43.92" spread="12.59"/>
                    <measurement group_id="O4" value="41.31" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Real iTBS</title>
          <description>iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes than standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals.</description>
        </group>
        <group group_id="E2">
          <title>Sham iTBS</title>
          <description>Sham iTBS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Myocardial infarction considered unrelated to the study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Transient non pulsating tinnitus (L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epileptiform discharges</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David H. Benninger, MD</name_or_title>
      <organization>Department of Neurology, Centre Hospitalier Universitaire Vaudois</organization>
      <email>David.Benninger@chuv.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

